Wilbanks Smith & Thomas Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-720	Closed	-$88K	–	786
2018 Q3	$88K	Buy	+720	New	+$84.8K	0.01%	569
2017 Q4	–	Sell	-6,447	Closed	-$717K	–	352
2017 Q3	$717K	Buy	+6,447	New	+$689K	0.06%	166

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's IBB Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of iShares Biotechnology ETF (IBB) in Q4 2018, closing a stake of 720 shares — an estimated $88K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in IBB in Q3 2017 and held it in 2 quarters. The position peaked at $717K in Q3 2017. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Wilbanks Smith & Thomas Asset Management reported no remaining iShares Biotechnology ETF position as of Q4 2018 after selling out during the quarter.
Wilbanks Smith & Thomas Asset Management sold 720 iShares Biotechnology ETF shares in Q4 2018, an estimated $88K.
Wilbanks Smith & Thomas Asset Management first reported a position in iShares Biotechnology ETF in Q3 2017 and held it in 2 quarters.
Wilbanks Smith & Thomas Asset Management's iShares Biotechnology ETF position peaked at $717K in Q3 2017.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.